Does BINIMETINIB Cause Malignant neoplasm progression? 131 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 131 reports of Malignant neoplasm progression have been filed in association with BINIMETINIB (MEKTOVI). This represents 1.9% of all adverse event reports for BINIMETINIB.
131
Reports of Malignant neoplasm progression with BINIMETINIB
1.9%
of all BINIMETINIB reports
54
Deaths
51
Hospitalizations
How Dangerous Is Malignant neoplasm progression From BINIMETINIB?
Of the 131 reports, 54 (41.2%) resulted in death, 51 (38.9%) required hospitalization, and 7 (5.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BINIMETINIB. However, 131 reports have been filed with the FAERS database.
What Other Side Effects Does BINIMETINIB Cause?
Off label use (902)
Death (719)
Nausea (657)
Fatigue (562)
Diarrhoea (521)
Product use in unapproved indication (508)
Pyrexia (490)
Neoplasm progression (387)
Vomiting (375)
Rash (360)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which BINIMETINIB Alternatives Have Lower Malignant neoplasm progression Risk?
BINIMETINIB vs BIOFLAVONOIDS
BINIMETINIB vs BIOTIN
BINIMETINIB vs BIPERIDEN
BINIMETINIB vs BIRCH TRITERPENES
BINIMETINIB vs BISACODYL